- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy (SMA)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1762KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 467KB)
Nusinersen – November 2020
Nusinersen: Solution for injection 12 mg in 5 mL: Spinraza®
Last updated
5 March 2021